Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00702494
Recruitment Status : Completed
First Posted : June 20, 2008
Last Update Posted : December 4, 2009
Thrombogenics NV
Information provided by:
BioInvent International AB

Brief Summary:

TB-403 is a monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding, growth of tumor vessels are inhibited and tumor growth prevented.

In this study we are investigating the tolerability and safety of TB-403 in patients with solid tumors who receives multiple intravenous doses of TB-403.

Condition or disease Intervention/treatment Phase
Solid Tumors Biological: TB-403 Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 21 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.
Study Start Date : June 2008
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
Multiple IV doses of TB-403, an antibody directed against PlGF
Biological: TB-403
Multiple IV

Primary Outcome Measures :
  1. Safety and tolerability of an anti-PlGF antibody [ Time Frame: 85 days ]

Secondary Outcome Measures :
  1. Determine multiple dose IV pharmacokinetics [ Time Frame: 85 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed malignity
  • Measurable disease
  • Performance status 1 or less (ECOG)

Exclusion Criteria:

  • Acute illness or infection
  • Concurrent second malignancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00702494

Onkologisk Klinik 5072 Finsencentret Rigshospitalet
Copenhagen, Denmark, DK-2100
Onkologisk Afdeling 54B1 Herlev Hospital
Herlev, Denmark, DK-2730
Sponsors and Collaborators
BioInvent International AB
Thrombogenics NV
Study Chair: Ulrik Lassen, MD, PhD Rigshospitalet, Denmark
Study Director: Lena Winstedt, PhD BioInvent International AB
Principal Investigator: Dorthe Nielsen, MD, PhD Herlev Hospital, Herlev, Denmark

Responsible Party: Steven Glazer, Senior Vice President, Development, Bioinvent International AB Identifier: NCT00702494     History of Changes
Other Study ID Numbers: 07-TB-403-02
EUDRACT No: 2008-001345-25
First Posted: June 20, 2008    Key Record Dates
Last Update Posted: December 4, 2009
Last Verified: December 2009

Keywords provided by BioInvent International AB:
placental growth factor
monoclonal antibody
Phase I
solid tumors
Patients with solid tumors

Additional relevant MeSH terms:
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs